

**AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

***Listing of claims:***

- 1 - 26. (Cancelled)
27. (Currently Amended) A method for enhancing the transduction efficiency of transduction of a nucleotide sequence of interest recombinant virus into a target cell a recombinant virus into a cell, comprising:
- (a) providing a recombinant adenovirus comprising a relaxin-encoding nucleotide sequence which is operatively linked to a regulatory sequence directing its expression, and a nucleotide sequence of interest to be delivered into the target cell; and
- (b) contacting the recombinant adenovirus virus with the target cell for the recombinant adenovirus to infect the target cell, wherein the recombinant virus comprises a relaxin-encoding nucleotide sequence operatively linked to a regulatory sequence directing its expression and the relaxin protein expressed from the infected target cell thereby enhances the efficiency of transduction of the recombinant adenovirus virus into the target cell.
28. (Currently Amended) The method according to claim 27, wherein the target cell is a cell in a tissue composed of cells interconnected to each other by an extracellular matrix.
29. (Previously Presented) The method according to claim 28, wherein the tissue is a tumor tissue.

30-31. (Cancelled)

32. (Currently Amended) The method according to claim 27 ~~claim 34~~, wherein the recombinant adenovirus comprises a deleted E3 region and the relaxin-encoding nucleotide sequence is inserted into the deleted E3 region.

33-38. (Cancelled)